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Mutations in PIGO, a Member of the
GPI-Anchor-Synthesis Pathway, Cause
Hyperphosphatasia with Mental Retardation
Peter M. Krawitz,1,2,3 Yoshiko Murakami,4 Jochen Hecht,2,3 Ulrike Kru¨ger,1 Susan E. Holder,5
Geert R. Mortier,6 Barbara Delle Chiaie,7 Elfride De Baere,7 Miles D. Thompson,8 Tony Roscioli,9,10
Szymon Kielbasa,11 Taroh Kinoshita,4 Stefan Mundlos,1,2,3 Peter N. Robinson,1,2,3,12,*
and Denise Horn1,12,*
Hyperphosphatasia with mental retardation syndrome (HPMRS), an autosomal-recessive form of intellectual disability characterized by
facial dysmorphism, seizures, brachytelephalangy, and persistent elevated serum alkaline phosphatase (hyperphosphatasia), was
recently shown to be caused by mutations in PIGV, a member of the glycosylphosphatidylinositol (GPI)-anchor-synthesis pathway.
However, not all individuals with HPMRS harbor mutations in this gene. By exome sequencing, we detected compound-heterozygous
mutations in PIGO, a gene coding for a membrane protein of the same molecular pathway, in two siblings with HPMRS, and we then
found by Sanger sequencing further mutations in another affected individual; these mutations cosegregated in the investigated families.
The mutant transcripts are aberrantly spliced, decrease the membrane stability of the protein, or impair enzyme function such that
GPI-anchor synthesis is affected and the level of GPI-anchored substrates localized at the cell surface is reduced. Our data identify
PIGO as the second gene associated with HPMRS and suggest that a deficiency in GPI-anchor synthesis is the underlying molecular
pathomechanism of HPMRS.More than 100 cell-surface proteins are attached to the
plasma membrane by covalent attachment to a glycosyl-
phosphatidylinositol (GPI) anchor that is assembled in
the endoplasmic reticulum (ER) and added to the C
terminus of the proteins. Biosynthesis of GPI anchors
involves more than 30 different genes.1 Genetic defects
in various components of the GPI-anchor-synthesis
pathway have been identified in a number of phenotypi-
cally diverse diseases that are now also referred to as defi-
ciencies of the GPI-anchor-glycosylation pathway; these
diseases belong to a subclass of congenital disorders of
glycosylation.2 Somatic mutations in the X-linked gene
phosphatidylinositol glycan class A (PIGA, MIM 311770)
in hematopoietic stem cells cause paroxysmal nocturnal
hemoglobinuria, which manifests as bone-marrow failure,
hemolytic anemia, smooth-muscle dystonias, and throm-
bosis (MIM 300818);3 germline mutations in this gene re-
sult in a severe neurological phenotype (MIM 300868).4
Germline mutations in PIGL (MIM 605947), a gene of
the early GPI-anchor glycosylation, cause CHIME syn-
drome (MIM 280000).5 Germline promoter mutations
in phosphatidylinositol glycan class M (PIGM [MIM
610273]; Figure 1) result in a severe deficiency of GPI-
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absence seizures (MIM 610293).6 An autosomal-recessive
syndrome caused by mutations in phosphatidylinositol
glycan class N (PIGN [MIM 606097]; Figure 1) and charac-
terized by dysmorphic features and multiple congenital
anomalies, severe neurological impairment, chorea, and
seizures leading to early death was described (MIM
614080).7 We have recently identified mutations in phos-
phatidylinositol glycan class V (PIGV [MIM 610274];
Figure 1) in individuals with HPMRS (MIM 239300).8–10
However, mutations in this gene are only found in approx-
imately half of the individuals with HPMRS. The purpose
of the current study was therefore to investigate the molec-
ular etiology of HPMRS in PIGV-negative individuals.
This study was approved by the Charite´ UniversityMedi-
cine ethics board, and informed consent was obtained
from responsible persons (parents) on behalf of all study
participants.
We performed whole-exome sequencing of all subjects
in family A (see Figure 2 for photos, Figure 4A for a pedi-
gree, and Table S1, available online, for clinical details).
The affected sisters, who are 12 and 15 years old, are
offspring of nonconsanguineous healthy parents of white
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Figure 2. Affected Individuals from Family A
(A) Facial appearance of individual II-1 at the age of 15 years.
(B) Individual II-2 at the age of 12 years.
(C) Nail hypoplasia of the second and fourth digits and absent nail
of the fifth digit in individual II-1.
(D) Broad hallux, small nails of the second and third toes, and
aplasia of the nails of the fourth and fifth digits in individual II-1.
Figure 1. Schematic Illustration of Biochemical Reactions of
Late GPI-Anchor Synthesis
The first, second, and third mannose residues are sequentially
transferred to GlcN-(acyl)PI by PIGM, PIGV, and PIGB. EtNP is
transferred to the first mannose by PIGN and to the thirdmannose
by PIGO and PIGF. Proteins for which the corresponding mutated
genes are known to cause congenital disorders of GPI-anchor
glycosylation are colored black.Genomic DNA of all family members was enriched with
the target region of all human consensus coding sequence
(CCDS) exons with Agilent’s SureSelect Human All Exon
Kit according to the manufacturer’s protocol. Single-read
clusters were then generated on the Cluster Station
(Illumina). The captured, purified, and clonally amplified
library targeting the exome was then sequenced on an Illu-
mina Genome Analyzer II. Whole-exome sequencing
(with two lanes of 120 bp unpaired reads) was performed
according to the manufacturer’s protocol and resulted in
more than 5 Gb of high-quality short-read sequence data.
Novoalign was used for the alignment of the sequence
reads to the human genome (GRCh37). The percentage
alignment of the reads to the targeted exomewas calculated
with Perl scripts and Bedtools.11 In each individual from
family A, around 90% of the target region was covered by
more than ten unique sequence reads (Figure S1). Samtools
and Perl scripts were used for the detection of single-
nucleotide variants as well as small indels (<20 bp) on the
short-read alignments.12–14 After common polymorphisms
that are also listed in dbSNP (build 132) were filtered out,
all detected variants were reduced to family-specific rare
variants and annotated with ANNOVAR.15 Assuming an
autosomal-recessive pattern of inheritance with 100%
penetrance of the phenotype, we filtered for genes with
rare homozygous or compound-heterozygous nonsynony-
mous variants in the affected siblings and identified
phosphatidylinositol glycan class O (PIGO) as the single
candidate gene (Table S2). The two detected variants in
PIGO were c.2869C>T (p.Leu957Phe) (NM_032634.3)
and c.2361dup (i.e., the mutation inserts an additional
cytosine residue into a homopolymer tract consisting of
seven cytosine residues), which led to a frameshift
(p.Thr788Hisfs*5) (Table S3). These variants were com-The Ampound heterozygous in the affected sisters and were thus
compatible with an autosomal-recessive mode of inheri-
tance. The mother was found to be heterozygous for
c.2869C>T, and the father was heterozygous for
c.2361dup (Figure 4 A and Figure S2).
After validating these variants by Applied Biosystems
Sanger sequencing, we subsequently screened 11 unrelated
individualswithout PIGVmutations formutations in PIGO.
We identified the compound-heterozygous candidate
mutations c.2869C>T and c.3069þ5G>A in individual
II-1 from family B (see Figure 3 for photos, Figure 4B for
a pedigree, Table S1 for clinical details, and Table S3). Indi-
vidual II-1 is the second child of nonconsanguineous
parents of European descent. The mother is heterozygous
for c.3069þ5G>A, and two unaffected siblings are also
heterozygous for one of the two detected mutations.
We hypothesized that the intronic mutation,
c.3069þ5G>A, identified in this family would interfere
with splicing of the transcript, and we analyzed the effect
of this variant on the RNA level. Approximately 3 mg of
RNA was isolated from a blood sample of the mother
carrying this variant and was used for the first-strand
cDNA synthesis. The quality of cDNA was verified by
amplification of b-actin cDNA. PIGO transcripts were
amplified and sequenced from this cDNA pool. The in-
tronic mutation c.3069þ5G>A results in an aberranterican Journal of Human Genetics 91, 146–151, July 13, 2012 147
Figure 3. Individual II-1 from Family B at
Different Ages
(A) When individual II-1 was 6 weeks of
age, facial dysmorphism included wide
and downward-slanting palpebral fissures,
a broad nasal bridge and tip, ptosis of the
right eye, a tented upper lip, large ears
with fleshy and uplifted ear lobules, and
facial asymmetry.
(B) Facial appearance when individual II-1
was 9 months old.
(C) At the age of 18 months.
(D) Nail hypoplasia of the second and fifth
digits and clinodactyly V.
(E) Hand radiograph when individual II-1
was 1 week old. Note brachytelephalangy
II to V, mostly affecting fingers II and V,
and a broad distal phalanx of the thumb.
(F) Nail hypoplasia of all toes.splicing product with a skipped exon 9 (Figure 4C); this
product was not observed in 13 cDNA controls (Figure S3).
The deletion of this 215 bp exon causes a frameshift
followed by a premature stop codon. According to data
from the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project, there is one heterozy-
gous individual for this intronic mutation out of 5,379
tested individuals, which is consistent with the expected
incidence of the disease.
In mammals, PIGO encodes a 1,089 amino acid protein,
GPI ethanolamine phosphate transferase 3 (also known as
phosphatidylinositol-glycan biosynthesis class O), that isfamily B
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Figure 4. Mutations in PIGO
(A) PIGO mutations in family A as demonstrated by whole-exome sequencing. Both affect
heterozygous for the PIGO mutations c.2869C>T and c.2361dup. The father is heterozygou
zygous for c.2869C>T.
(B) The affected individual from family B is compound heterozygous for c.2869C>Tand c.306
II-3 are heterozygous only for c.3069þ5G>A, and her healthy brother II-2 is heterozygous o
(C) The intronic mutation results in an aberrant splicing product of transcript NM_032634,
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The substitution p.Leu957Phe affects
the second of four leucine residues in
a polyleucine stretch within a hydro-
phobic transmembrane domain of
PIGO. The residue is evolutionarilyhighly conserved in most species, including mammals,
frogs, and zebrafish (Figure S4), and the effect of the de-
tected substitution was classified as disease causing by
MutationTaster18 and Polyphen.19 The heterozygote fre-
quency of all three alleles in the European population
is below 0.0005, which is expected for rare recessive
disorders.20
We first investigated the influence of two PIGO muta-
tions on PIGO function. To test the variants p.Leu957Phe
and p.Thr788Hisfs*5 for effects on PIGO function, we
cloned a human PIGO cDNA from a cDNA library derived
from Hep3B (a hepatoma cell line) cells, tagged it withc.3069+5G>A
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Figure 5. PIGO Activity Is Required for Linking GPI-Anchored Substrates to the Cell Membrane
(A) PIGO-deficient CHO cells were transiently transfected with human wild-type (dotted lines), p.Thr788Hisfs*5 (dashed line), or
p.L957F (solid lines) PIGO cDNA expression constructs. Restoration of the levels of CD59 at the cell surface and of uPAR was assessed
2 days later. Wild-type PIGO efficiently restored levels of CD59 at the cell surface and of uPAR, whereas Thr788Hisfs*5 PIGO did not
restore the level of CD59 at all and the Leu957Phe PIGO induced only very low levels of CD59 and uPAR. The shadowed area indicates
an empty-vector transfectant (control).
(B) PIGO levels. The level of the truncated Thr788Hisfs*5 PIGO (lane 3) was about 2.53 higher than that of wild-type PIGO (lane 2), and
the level of Leu957Phe PIGO (lane 4) was slightly lower than that of wild-type PIGO (lane 2).
(C) The level of PLAP at the cell surface after cotransfection with PIGO into PIGO-deficient CHO cells. PIGO-deficient CHO cells were
transiently transfected with pME HA-PLAP together with pME PIGO (dotted line) or an empty vector (solid line). The level of PLAP
at the cell surface was analyzed by fluorescence-activated cell sorting. PLAP activity was measured in culture medium and cell lysates
after cotransfection of PLAP and PIGO cDNAs into PIGO-deficient CHO cells. Relative ALP activity was measured in culture medium
(black bars) and in cell lysates (dark gray bar) against the total ALP activity in PIGO-restored CHO cells. Restoration of PIGO activity
reduces ALP activity in the medium and increases activity at the cell membrane.FLAG at the N-terminus, and subcloned it into pME.21
PIGO mutants were generated by site-directed mutagen-
esis. Mutant and wild-type PIGO plasmids were transfected
by electroporation into human CD59-expressing PIGO-
deficient CHO cells that were derived from aerolysin-
resistant clones from chemically mutagenized Chinese
hamster ovary (CHO) cells as previously described.22 We
determined the levels of GPI-APs CD59 (at the cell surface)
and endogenous urokinase plasminogen activator receptor
(uPAR) by staining cells with anti-CD59 (5H8) and anti-
hamster uPAR antibodies, and we used a flow cytometer
(Cant II; BD Biosciences, Franklin Lakes, NJ) with Flowjo
software (Tommy Digital, Tokyo, Japan) to analyze them.
Wild-type PIGO efficiently restored the levels of CD59
at the cell surface and of uPAR, whereas p.Thr788Hisfs*5
PIGO did not rescue protein levels at all and the Leu957Phe
PIGO induced only very low levels of CD59 and uPAR
(Figure 5A). Levels of PIGO in cells were determined by
immunoblot analysis. Band intensities of endogenous glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) were
used as loading controls. Compared with that of wild-
type PIGO, the level of Leu957Phe was slightly reduced,
whereas the c.2361dup mutation resulted in an increased
level of the truncated Thr788Hisfs* protein (Figure 5B).
The three individuals carrying PIGOmutationswere born
with normal measurements, but they had anal stenosis
(individuals II-1 and II-2 from family A) or anal atresiaThe Amwith perineal fistula (individual II-1 from family B)
(Figures 2 and3 andTable S1). In individual II-1 from family
B, additional malformations included an atrial septal
defect, peripheral pulmonary stenosis, left coronal synos-
tosis resulting in plagiocephaly, and an enlarged supraten-
torial ventricular system.Growthdevelopmentwasdelayed
in individuals II-1 from family A and II-1 from family B,
who also showed marked microcephaly of 5.5 standard
deviations (SDs) at the age of 20 months. Psychomotor
development was severely retarded in individuals II-1
from family A and II-1 from family B and was moderately
delayed in individual II-2 of family A. Individual II-1 from
family B developed tonic-clonic seizures at the age of
21 months and died at the age of 22 months as a result of
a convulsive crisis. Their common facial signs included
wide-set eyes that appeared large because of long palpebral
fissures, a short nosewith a broadnasal bridge andnasal tip,
and a tented mouth. Their fingers showed nail hypoplasia,
especially of the second, fourth, and fifth digits, and absent
nails of the fifth digits (individuals II-1 and II-2 from family
A). Their halluces were broad, but the toes showed small
nails or aplasia of nails, especially of the fourth and fifths
digits. Serum alkaline phosphatase (ALP) activity was
elevated in repeated tests (1,872 U/l in individual II-1 and
1,381U/l in individual II-2 from family A [the normal range
is 200–700 U/l] and 1,436 U/l in individual II-1 from family
B [the normal range is 124–341 U/l]).erican Journal of Human Genetics 91, 146–151, July 13, 2012 149
We next hypothesized that the hyperphosphatasia
observed in our patients was due to the PIGO defect. We
performed measurements of relative placental ALP (PLAP)
activity in cell lysates and medium of PIGO-deficient
CHO cells, and we compared them with those of wild-
type cells. The mutant CHO cells were cotransfected with
pME HA-PLAP (a previously described construct23), pME
Luc, and either a PIGO-expressing plasmid (pME F-PIGO)
or an empty vector (pME). Media were changed 6 hr later,
and the ALP activity in cell lysates and culture media was
measured on the following day with the SEAP assay kit
(Clontec). Luciferase activities of cell lysates weremeasured
with the Luciferase assay kit (Promega) and were used for
the normalization of gene expression. Relative activity in
the culture medium was the ratio of normalized ALP
activity in the culture medium to the total normalized
ALP activity of PIGO-rescued cells. PLAP failed to express
on the cell surface (Figure 5C, upper panel), but 90% of
the activity was found to reside in the medium from the
PIGO-deficient cells (Figure 5C, lower panel). In contrast,
transfection with the PIGO-expressing vector restored the
surface expression (Figure 5C, upper panel) and prevented
oversecretion of PLAP; the majority of PLAP activity re-
mained in the cell (Figure 5C, lower panel). These results
indicate that hyperphosphatasia is a result of the release
of ALP into serum, which itself is due to a GPI deficiency
caused by the PIGO mutation.
A combination of hyperphosphatasia, intellectual
disability, and various neurological problems, mainly
seizures, has been described by different authors, and the
condition has been designated as ‘‘hyperphosphatasia
with mental retardation.’’24,25 In a subset of individuals
affected by HPMRS in addition to specific facial features
and brachytelephalangy, missense mutations of PIGV
have been identified.8–10 Anorectal malformations, Hirsch-
sprung disease, and other organ malformations broaden
the clinical spectrum associated with PIGV mutations.8–10
Because PIGV mutations are only found in some of the
affected individuals with the core manifestations, genetic
heterogeneity seems to be likely. Our study identifies
compound-heterozygous mutations in PIGO as a further
genetic cause of HPMRS. The characteristic facial appear-
ance, moderate-to-severe developmental delay, hypo-
plastic or even absent terminal phalanges (including nails),
and hyperphosphatasia were present in all affected individ-
uals studied here. In individual II-1 from family B, a signifi-
cant deceleration of head growth was seen during infancy
(the occipital frontal circumference fell to more than 5
SDs below the mean). Whereas individuals carrying PIGV
mutations often show growth parameters at or above the
mean, individuals with PIGO mutations seem to show
more pronounced growth delay. Malformations of the
urinary system and heart should be considered as part of
this condition.
Our results suggest that PIGO is essential for GPI
anchoring of GPI-APs alkaline phosphatase, CD59, and
uPAR, and we show that the two tested PIGO mutations150 The American Journal of Human Genetics 91, 146–151, July 13, 2have a deleterious effect on PIGO function in a cell-based
assay.We have recently shown that GPI transamidase plays
a critical role in the secretion of proproteins in the absence
of mature GPI, as observed in PIGV-deficient HPMRS.23
The presence of mannose residue of immature GPI is crit-
ical for cleavage of the proproteins by GPI transamidase,
which provides an explanation for the observation that
PIGV deficiency, which affects a relatively late step in the
GPI-biosynthesis pathway, leads to hyperphosphatasia,
whereas PIGM deficiency, which leads to a defect in the
first GPImannosyltransferase, does not.23 This observation
provides a plausible explanation for the fact that muta-
tions in both PIGV, which encodes a protein that transfers
the second mannose residue to the GPI anchor,26 and
PIGO, which encodes a protein that transfers phosphoe-
thanolamine to the third mannose residue of the GPI
anchor,16 are associated with HPMRS. Determining
whether there are any clinical differences between these
groups will require phenotypic characterization of more
individuals with PIGO and PIGV mutations. Given the
fact that neither PIGV nor PIGOmutations were identified
in ten individuals with a similar phenotype, it seems likely
that mutations in other GPI-pathway genes might repre-
sent further etiologies of HPMRS.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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